Abstract
Direct Oral Anti-Coagulants (DOACs) are the primary treatment for the long-term prevention of stroke in patients with atrial fibrillation. Strict adherence to DOAC therapy is crucial and must be maintained over the long term. Therefore, predicting long-term adherence is valuable for identifying patients at risk of non-adherence. We developed a novel method for predicting long-term adherence using first-order Markov models to assess adherence in new DOAC users during years 2–5. The prediction utilized age, CHA2DS2-VASc score, and first-year adherence data as predictors. Adherence was measured by calculating the proportion of days covered within consecutive 90-day windows, which were then stratified into deciles. We subsequently calculated the probability of a patient being in a specific adherence decile. The developed model demonstrated good calibration. We discovered that missing even 1 day of treatment per month in the first year was predictive of a lower likelihood of achieving the highest adherence decile in years 2–5. Additionally, we noted a non-linear relationship between age and adherence; adherence increased linearly with age but plateaued around age 75. This innovative approach to modelling and predicting adherence to DOACs for long-term therapy can help identify patients at risk of low adherence and may be applicable to other chronic medications.
| Original language | English |
|---|---|
| Article number | 1673919 |
| Journal | Frontiers in Pharmacology |
| Volume | 16 |
| DOIs | |
| State | Published - 1 Jan 2025 |
Keywords
- Markov
- adherence
- atrial fibrillation
- direct oral anti-coagulants
- prediction
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)